New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:33 EDTCYTRCytRx receives FDA approval to continue aldoxorubicin clinical trial
CytRx announced it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas. The clinical trial is scheduled to begin this quarter. For purposes of the clinical trial, disease progression is defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion.
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
10:08 EDTCYTRHigh option volume stocks
High option volume stocks: HIL AEO HCI EWU WHZ SFUN GNC ON CYTR JBHT
09:07 EDTCYTRCytRx reports interim analysis from two aldoxorubicin combination studies
Subscribe for More Information
08:30 EDTCYTRCytRx sell-off brings attractive entry point, says FBR Capital
Subscribe for More Information
May 1, 2015
06:12 EDTCYTRCytRx reports Q1 EPS (31c), consensus (21c)
Subscribe for More Information
April 29, 2015
09:08 EDTCYTRCytRx reports on aldoxorubicin shows brain cancer results in publication
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use